News

  • 24 June 2019

    Immugenyx develops new type of humanised mouse ApbHC

    Immugenyx, a wholly-owned subsidiary of Hemogenyx Pharmaceuticals, has developed a new type of humanised mouse called Advanced peripheral blood Hematopoietic Chimera (ApbHC) to help develop treatments against unknown human-specific pathogens.

Close
Close
Close

Go Top